Li X, Yu H, Fu X, et al. - Researchers report the outcomes of patients with primary and secondary extranodal natural killer (NK)/T-cell lymphoma (NKTL) of central nervous system (CNS). A total of 19 of 414 patients (4.59%) with ENKL followed were diagnosed with CNS involvement between 2006 and 2020. Among participants, primary CNS NKTL was present in two patients, and secondary CNS invasion was evident in 17 patients. Death occurred in 10 patients and 9 patients survived. A median overall survival time of 55 months was reported, and the median survival time post-CNS invasion was identified to be 17 months. The 5-year cumulative survival likelihood was estimated to be 45.7%. Overall, patients with NK/T-cell lymphoma prognostic index risk group III/IV form a patient population which is eligible for CNS risk assessment and prophylaxis treatment. Regarding treatment, clinicians can select systemic therapy based on methotrexate combined with radiotherapy and intrathecal chemotherapy.